52-kDa Ro/SSA Epitopes Preferentially Recognized by Antibodies from Mothers of Children with Neonatal Lupus and Congenital Heart Block

DSpace/Manakin Repository

52-kDa Ro/SSA Epitopes Preferentially Recognized by Antibodies from Mothers of Children with Neonatal Lupus and Congenital Heart Block

Citable link to this page

. . . . . .

Title: 52-kDa Ro/SSA Epitopes Preferentially Recognized by Antibodies from Mothers of Children with Neonatal Lupus and Congenital Heart Block
Author: Fritsch, Christine; Hoebeke, Johan; Dali, Hayet; Isenberg, David A; Meyer, Olivier; Muller, Sylviane; Ricchiuti, Vincent

Note: Order does not necessarily reflect citation order of authors.

Citation: Fritsch, Christine, Johan Hoebeke, Hayet Dali, Vincent Ricchiuti, David A Isenberg, Olivier Meyer, and Sylviane Muller. 2006. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Research & Therapy 8(1): R4.
Full Text & Related Files:
Abstract: Neonatal lupus erythematosus is a rare disorder caused by the transplacental passage of maternal autoantibodies. The 52-kDa Ro/SSA antigen (Ro52) ribonucleoprotein represents an antigenic target strongly associated with the autoimmune response in mothers whose children have neonatal lupus and cardiac conduction disturbances, mainly congenital heart block. The objective of this study was to identify putative Ro52/60-kDa Ro/SSA antigen (Ro60) epitopes associated with neonatal lupus and congenital heart block. The reactivity of IgG antibodies present in the sera from mothers with systemic lupus erythematosus and Sjögren's syndrome and in the sera from asymptomatic mothers (a longitudinal study of 192 samples from 66 subjects) was investigated by ELISA using Ro52, Ro60 and 48-kDa La/SSB antigen proteins, as well as 45 synthetic peptides, 13–24 residues long, of Ro52/Ro60 proteins. One to 19 samples collected before, during and after pregnancy were available for each mother. Forty-three disease controls selected randomly and normal sera were tested in parallel. Although no differences were found between Sjögren's syndrome and asymptomatic mothers of group I, who had at least one infant with neonatal lupus, and of group II, who had healthy babies only, significant differences were observed between lupus mothers from both groups. In the former group of lupus mothers, a significantly higher frequency of antibodies to Ro52 peptides 107–122 and 277–292 was observed. Between 18 and 30 weeks of gestation, the period of risk, there was clearly an elevated level of antibodies reacting with Ro52 peptides 1–13, 277–292 and 365–382. Antibodies to Ro52 peptide 365–382 have been shown previously to cross-react with residues 165–185 of the heart 5-HT4 serotoninergic receptor, and might be pathologically important. The level of these Ro52 antibody subsets decreased at the end of pregnancy and after delivery. IgG antibodies to Ro52 peptides 1–13, 107–122, 277–292 and 365–382 may therefore represent important biomarkers to predict a complication in pregnant lupus women with Ro52 antibodies.
Published Version: doi://10.1186/ar1848
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526571/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5332929

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters